bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $82.78, but opened at $78.31. bioMerieux shares last traded at $78.31, with a volume of 58 shares changing hands.

Analyst Upgrades and Downgrades

BMXMF has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Morgan Stanley lowered bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. Piper Sandler initiated coverage on bioMerieux in a report on Thursday, June 11th. They set a “neutral” rating on the stock. Zacks Research raised bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. Finally, UBS Group lowered bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Five equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

bioMerieux Stock Performance

The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The company’s fifty day moving average price is $82.13 and its two-hundred day moving average price is $102.95.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.